Research Laboratory of Microbiology, Biochemistry and Immunogenetics, Saint-Petersburg Research Institute of Phthisiopulmonology, Saint Petersburg 191036, Russia.
D S Esmedlyaeva studies the effectiveness of new chemotherapy treatments against various strains of drug-resistant tuberculosis. This includes analyzing how specific strains affect infected patients, particularly in terms of lung health and the body's immune response. For example, she has researched the impact of the highly virulent Beijing 396 strain compared to less harmful strains like Beijing 6691 and LAM 7074, revealing that some strains cause more severe health issues and may be harder to treat. Her research aims to improve treatment strategies for patients suffering from drug-resistant TB.
Key findings
Patients with the Beijing 396 strain experienced significantly more lung damage compared to those with Beijing 6691 and LAM 7074 strains.
Treatment reduced inflammation in the lungs but did not fully eliminate the bacteria, with a slight increase in bacterial load observed after nearly six months.
The study highlighted that the response to chemotherapy varies significantly across different TB strains, emphasizing the need for tailored treatment approaches.
Frequently asked questions
Does Dr. Esmedlyaeva study tuberculosis?
Yes, she focuses specifically on drug-resistant strains of tuberculosis and their treatment.
What treatments has Dr. Esmedlyaeva researched?
She has researched new chemotherapy drugs aimed at treating drug-resistant tuberculosis in various mouse models.
Is Dr. Esmedlyaeva's work relevant to patients with TB?
Absolutely, her research is vital for developing better treatment strategies for patients suffering from drug-resistant tuberculosis.
Publications in plain English
Novel use of bisphosphonates to improve surgical outcomes in experimental bone tuberculosis.
Plain English This study examined the use of a drug called pamidronate to enhance bone healing after surgery for a type of bone infection caused by tuberculosis in rabbits. The results showed that pamidronate improved bone regrowth, reduced bone loss, and increased bone density at three and six months after surgery compared to those who only received standard TB treatment. This matters because it suggests that adding pamidronate to treatment could lead to better recovery outcomes for patients suffering from this challenging condition.
Who this helps: Patients with bone tuberculosis undergoing surgery.
Insight into blood proteinase-inhibitor system and pathogenesis of renal tuberculosis induced by phylogenomically different Mycobacterium tuberculosis strains in rabbit model.
2025
BMC nephrology
Esmedlyaeva D, Mokrousov I, Alekseeva N, Blum N, Dyakova M +6 more
Plain English This study examined how different strains of Mycobacterium tuberculosis affect kidney health in rabbits with renal tuberculosis. It found that a more virulent strain (H37Rv) caused significant changes in certain blood proteins and less severe damage to kidney structures compared to a less virulent, multidrug-resistant strain (5582); specifically, after 22 weeks, the virulent strain led to higher levels of certain enzymes (like MMP-9) but less overall kidney tissue damage than the other strain. Understanding these differences helps pinpoint the varying impacts of tuberculosis strains on kidney health, which is crucial for developing targeted treatments.
Who this helps: Patients with renal tuberculosis and their healthcare providers.
Long-term chemotherapy of C57BL/6 mice infected with epidemiologically important Mycobacterium tuberculosis strains and molecular insight into host-pathogen interplay.
2025
Microbial pathogenesis
Vinogradova T, Zabolotnykh N, Dogonadze M, Dyakova M, Esmedlyaeva D +6 more
Plain English This study looked at how effective new chemotherapy drugs are against different strains of drug-resistant tuberculosis (TB) bacteria in mice. The researchers found that while treatment helped reduce lung damage and inflammation overall, some strains caused more serious illness than others: the highly virulent Beijing 396 strain resulted in the most lung damage, while the less harmful Beijing 6691 and LAM 7074 strains were easier to treat. Interestingly, after nearly six months of treatment, the bacterial load in the lungs of most treated mice increased slightly, highlighting the challenges in fully clearing the infection.
Who this helps: This research assists doctors and researchers in developing better treatment strategies for patients with drug-resistant TB.
Mesenchymal stem cells-derived extracellular vesicles for therapeutics of renal tuberculosis.
2024
Scientific reports
Yudintceva N, Bobkov D, Sulatsky M, Mikhailova N, Oganesyan E +17 more
Plain English This research studied how mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) could improve treatment for renal tuberculosis, a serious infection in the kidneys. In tests on rabbits, adding MSC-EVs to standard tuberculosis treatment led to a significant increase in anti-inflammatory markers and a decrease in inflammation, suggesting better kidney health. This approach may help shorten treatment time and improve recovery outcomes for patients with renal tuberculosis.
Who this helps: This benefits patients with renal tuberculosis and their doctors.
Comparison of Autografts and Biodegradable 3D-Printed Composite Scaffolds with Osteoconductive Properties for Tissue Regeneration in Bone Tuberculosis.
2023
Biomedicines
Vinogradova TI, Serdobintsev MS, Korzhikova-Vlakh EG, Korzhikov-Vlakh VA, Kaftyrev AS +8 more
Plain English This study looked at two methods for repairing bone damage caused by tuberculosis in rabbits: using pieces of the rabbits' own bone (autografts) versus using a 3D-printed biodegradable scaffold. It found that both methods helped in regenerating bone, but the 3D-printed scaffolds showed promise in facilitating healing by supporting new bone growth and reducing inflammation. This matters because finding an effective way to repair bone damaged by tuberculosis could improve treatment outcomes for patients with this infection.
Who this helps: Patients with bone tuberculosis.
Plain English This study looked at how certain proteins in the blood relate to the severity and treatment of pulmonary tuberculosis (TB) in patients. Researchers found increased levels of MMP-1 and MMP-9 in patients with more severe TB, while other proteins remained unchanged during treatment. This helps doctors understand how the body responds to TB and can improve predictions about how effective treatments will be.
Who this helps: This helps patients with pulmonary tuberculosis and their doctors by providing better tools for monitoring treatment progress.